Stockreport

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

Cellectis S.A. - American Depositary Shares  (CLLS) 
Last cellectis s.a. - american depositary shares earnings: 3/4 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: cellectis.com/en/investors
PDF NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pionee [Read more]